Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495920 | 0.89 | MAPT (0.50) | KMT2AMEN1KCNN4KCNA3LMNA | |
| SCHEMBL13273471 | 0.85 | KCNN4 (0.51) | KMT2AMEN1KCNN4KCNA3MAPT | |
| SCHEMBL17678694 | 0.80 | KDM4E (0.58) | KMT2AMEN1LMNATSHRKDM4E | |
| SCHEMBL19150534 | 0.79 | KMT2A (0.42) | KMT2AMEN1KCNN4KCNA3LMNA | |
| SCHEMBL7714538 | 0.78 | KMT2A (0.48) | KMT2AMEN1KCNN4KCNA3LMNA | |
| SCHEMBL19150712 | 0.78 | ALDH1A1 (0.47) | KMT2AMEN1LMNATSHRMAPT | |
| SCHEMBL31058571 | 0.77 | KCNN4 (0.51) | KMT2AMEN1KCNN4KCNA3MAPT | |
| SCHEMBL25562472 | 0.77 | KCNN4 (0.51) | KMT2AMEN1KCNN4KCNA3MAPT | |
| SCHEMBL6600485 | 0.75 | KMT2A (0.49) | KMT2AMEN1KCNN4KCNA3LMNA | |
| SCHEMBL6600482 | 0.75 | KMT2A (0.49) | KMT2AMEN1KCNN4KCNA3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| US-8273754-B2 | Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds | ARQULE, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273754-B2 | Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds | ARQULE, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273754-B2 | Substituted 1H-pyrazolo[3,4-D]pyrimidine-6-amine compounds | ARQULE, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| US-8202858-B2 | Vasopressin V1a antagonists | VANTIA LIMITED (GB) | 2012-06-19 | — | — | US | disclosed |
| EP-2256119-B1 | Vasopressin V1a antagonists | VANTIA LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| EP-2256119-B1 | Vasopressin V1a antagonists | VANTIA LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | BATT ANDRZEJ ROMAN (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| EP-1781661-A2 | VASOPRESSIN V1A ANTAGONISTS | Ferring B.V. (NL) | 2007-05-09 | — | — | EP | disclosed |
| EP-1632494-A1 | Vasopressin v1a antagonists | FERRING B.V. (NL) | 2006-03-08 | — | — | EP | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
| US-5849735-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| EP-0804420-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | American Cyanamid Company (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996022282-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101082-A1 | VASOPRESSIN V1A ANTAGONISTS | AVPR1A, AVPR2, AVPR1B | KMT2A 2204/4885MEN1 977/4885KCNN4 511/4885 |
| US-20090029965-A1 | Vasopressin V1a Antagonists | AVPR1A, AVPR2, AVPR1B | KMT2A 2204/4885MEN1 977/4885KCNN4 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.